Kadyrkhodjayeva N1*, Prokhorova A2
1Doctor of Medical Science, Tashkent Medical Academy, Farobi 2, Olmazor District, Tashkent, Uzbekistan
2Department of Neurology, Tashkent Medical Academy, Farobi 2, Olmazor District, Tashkent, Uzbekistan
Corresponding Author: Nigora Kadyrkhodjayeva, MD
Address: Doctor of Medical Science, Tashkent Medical Academy, Farobi 2, Olmazor District, Tashkent, Uzbekistan; Email: firstname.lastname@example.org
Received date: 03 March 2020; Accepted date: 11 April 2020; Published date: 02 May 2020
Aim: The purpose of the study was to review the efficacy, safety, and tolerability of botulinum toxin A (BTX-A) as a prophylactic treatment in adults with chronic daily headache (CDH).
Material and methods: The research participated in 100 patients with CDH comparing two groups of patients. Group I, 54 patients (31 women and 23 men) treated by BTX-A and group II, 46 patients (27 women and 21 men) treated with the classical method, with an average age of 35 ± 9 years. The patient’s condition in group I was assessed on the third day, on the 7th day and the 15th day after the BTX-A injection and assessed every 15 days for 3 months, in group II the patients were evaluated every 15 days.
Results: After 3 months headache severity in group I: 2 (3,7%) patients had no changes, 7 (12,9%) patients with less than 50 percent reduction in pain, 23 (42,6%) reported 70 to 95 percent pain relief, and 22 (40,8%) had complete relief. Group II: 12 (26,1%) patients had no changes, 16 (34,8%) patients with less than 50 percent reduction in pain, 10 (21,7%) reported 70 to 95 percent pain relief, and 8 (17,4%) had complete relief. The mean change from baseline frequency of headaches ranged from 3 ± 1 headaches per 30‐day periods in-group I and 7 ± 2 headaches in group II. The patient’s in-group I used painkillers for an acute headache 4 ± 1 day, compared to 10 ± 2 days for the group II per 30-day period.
Conclusion: In this study, BTX-A injections are safe, well-tolerated, not any treatment-related serious adverse events reported. BTX-A injections recommended optimizing clinical outcomes for patients with CDH without using other prophylactic medications. Although, further observations are needed.
Citation: Kadyrkhodjayeva N, Prokhorova A. Management of Chronic Daily Headache with Focus on Botulinum Toxin Type A. J Health Care and Research. 2020 May 2;1(2):38-42.
Copyright © 2020 Kadyrkhodjayeva N, Prokhorova A. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: BTX-A Injection; Daily Chronic Headache; Primary Headache
Abbreviations: BTX-A: Botulinum Toxin Type A; CDH: Chronic Daily Headache; CTTH: Chronic Tension‐Type Headache; FSFD: Fixed‐Site and Fixed‐Dose; FTP: Follow-The-Pain; CM: Chronic Migraine